Zobrazeno 1 - 10
of 42
pro vyhledávání: '"Gill Worthy"'
Autor:
Marie Westwood, Bram Ramaekers, Sabine Grimm, Gill Worthy, Debra Fayter, Nigel Armstrong, Titas Buksnys, Janine Ross, Manuela Joore, Jos Kleijnen
Publikováno v:
Health Technology Assessment, Vol 25, Iss 33 (2021)
Background: Early diagnosis of acute myocardial infarction is important, but only 20% of emergency admissions for chest pain will actually have an acute myocardial infarction. High-sensitivity cardiac troponin assays may allow rapid rule out of myoca
Externí odkaz:
https://doaj.org/article/fd1acba4d09b469eb9f565adbc34bcb0
Autor:
Nigel Armstrong, Nasuh Büyükkaramikli, Hannah Penton, Rob Riemsma, Pim Wetzelaer, Vanesa Huertas Carrera, Stephanie Swift, Thea Drachen, Heike Raatz, Steve Ryder, Dhwani Shah, Titas Buksnys, Gill Worthy, Steven Duffy, Maiwenn Al, Jos Kleijnen
Publikováno v:
Health Technology Assessment, Vol 24, Iss 51 (2020)
Background: There have been no licensed treatment options in the UK for treating thrombocytopenia in people with chronic liver disease requiring surgery. Established management largely involves platelet transfusion prior to the procedure or as rescue
Externí odkaz:
https://doaj.org/article/c59e5b6200d84298a2c9f75acd4ef74a
Autor:
Rob Riemsma, Isaac Corro Ramos, Richard Birnie, Nasuh Büyükkaramikli, Nigel Armstrong, Steve Ryder, Steven Duffy, Gill Worthy, Maiwenn Al, Johan Severens, Jos Kleijnen
Publikováno v:
Health Technology Assessment, Vol 20, Iss 17 (2016)
Background: In recent years, meters for continuous monitoring of interstitial fluid glucose have been introduced to help people with type 1 diabetes mellitus (T1DM) to achieve better control of their disease. Objective: The objective of this project
Externí odkaz:
https://doaj.org/article/cef3222f3338437f8d6576a53d7d4d0a
Autor:
Ben Wijnen, Willem Witlox, Robert Wolff, Debra Fayter, Bram Ramaekers, Thomas Otten, Steve Ryder, Pawel Posadzki, Gill Worthy, Lisa Stirk, Nigel Armstrong, Jos Kleijnen, Manuela Joore
Publikováno v:
PharmacoEconomics.
Fenfluramine, tradename Fintepla ®, was appraised within the National Institute for Health and Care Excellence (NICE) single technology appraisal (STA) process as Technology Appraisal 808. Within the STA process, the company (Zogenix International)
Autor:
Nigel Armstrong, Sabine Grimm, Debra Fayter, Bram Ramaekers, Janine Ross, Titas Buksnys, Richard Body, Adam Timmis, Paul Collinson, Marie Westwood, Gill Worthy, Jos Kleijnen, Nicholas L. Mills
Publikováno v:
Clinical Chemistry. 67:237-244
Background We assessed the accuracy and clinical effectiveness of high-sensitivity cardiac troponin (hs-cTn) assays for early rule-out of non-ST-segment elevation myocardial infarction (NSTEMI) in adults presenting with acute chest pain. Methods Sixt
Autor:
Marie Westwood, Willem J.A. Witlox, Debra Fayter, Ben F. M. Wijnen, Kate Misso, Steve Ryder, Titas Buksnys, Nigel Armstrong, Gill Worthy, Bram Ramaekers, Manuela A. Joore, Sabine Grimm, Jos Kleijnen
Publikováno v:
Pharmacoeconomics. 38(10):1043-1053
GW Research Ltd. provided two separate, but similar, submissions to the National Institute for Health and Care Excellence (NICE) on the clinical and cost-effectiveness of cannabidiol (CBD) 10 mg/kg/day, trade name Epidyolex(R), for the adjunctive tre
Autor:
Vanesa Huertas Carrera, Svenja Petersohn, Gill Worthy, Heike Raatz, Alastair K Denniston, Annette Chalker, Manuela A. Joore, Xavier Pouwels, Rob Riemsma, Caro Noake, Nigel Armstrong, Jos Kleijnen, Willem J.A. Witlox, Dhwani Shah
Publikováno v:
Pharmacoeconomics
The National Institute for Health and Care Excellence (NICE) invited Alimera Sciences, the company manufacturing fluocinolone acetonide intravitreal implant (FAc) 0.19 mg (tradename ILUVIEN), to submit evidence on the clinical and cost-effectiveness
Autor:
Vanessa Huertas Carrera, Steve Ryder, Dhwani Shah, Bettina Buchheister, Irmgard Boesl, Gill Worthy, Ingo Sabatschus, Titas Buksnys, Hiltrud Liedgens, Nigel Armstrong, Jos Kleijnen, Stephanie L. Swift, Caro Noake
Publikováno v:
Current Medical Research and Opinion. 36:101-115
Objective: Neuropathic pain prevalence is estimated between 7% and 10% of the population. International guidelines recommend a variety of drugs at different therapy lines for pain relief. However, side effect profiles, for example, prompted the UK go
Autor:
Manuela A. Joore, Jos Kleijnen, Alastair K Denniston, Svenja Petersohn, Vanesa Huertas Carrera, Gill Worthy, Annette Chalker, Willem J.A. Witlox, Caro Noake, Nigel Armstrong, Xavier Pouwels, Heike Raatz, Rob Riemsma
Publikováno v:
Pharmacoeconomics, 38(6), 649-651. Adis International Ltd
PharmacoEconomics, 38, 649-651. Adis International Ltd
PharmacoEconomics, 38, 649-651. Adis International Ltd
Autor:
Debra Fayter, Nasuh Büyükkaramikli, Kate Misso, Frederick W. Thielen, Ching-Yun Wei, Gill Worthy, Isaac Corro Ramos, Rob Riemsma, Nigel Armstrong, Jos Kleijnen, Vanesa Huertas Carrera
Publikováno v:
Pharmacoeconomics. 37(8):975-984
The National Institute for Health and Care Excellence (NICE), as part of the institute’s single technology appraisal (STA) process, invited the company that makes obinutuzumab (Roche Products Limited) to submit evidence of the clinical and cost eff